Avasimibe
CAS: 166518-60-1
Rif. 3D-RGA51860
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione |
Informazioni sul prodotto
- ((2,4,6-Tris(1-Methylethyl)Phenyl)Acetyl)Sulfamicacid2,6-Bis(1-Methylethyl)Phenylester
- 2,6-Di(Propan-2-Yl)Phenyl {[2,4,6-Tri(Propan-2-Yl)Phenyl]Acetyl}Sulfamate
- 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate
- Avasimin
- Ci 1011
- N-(2,6-Dipropan-2-Ylphenoxy)Sulfonyl-2-(2,4,6-Tripropan-2-Ylphenyl)Acetamide
- N-[(2,6-Diisopropylphenoxy)Sulfonyl]-2-(2,4,6-Triisopropylphenyl)Acetamide
- Pd 148515
- Sulfamic acid, N-[2-[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester
- Sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester
- Vedi altri sinonimi
Avasimibe is a drug that inhibits the enzyme DPP-IV and prevents the degradation of DPP-IV substrates, such as peptides, proteins, and lipids. It also has other pharmacological effects such as inhibiting the mitochondrial membrane potential and inducing cell lysis. Avasimibe is used to treat atherosclerosis by preventing cholesterol from being absorbed by cells. It is also used in cancer treatment for its ability to inhibit viral life and reduce tumor size. In addition, avasimibe is able to inhibit BCR-ABL kinase activity and induce apoptosis in human leukemia cells.